Chang‐Ki Min

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Shaji Kumar, Meletios Α. Dimopoulos, Efstathios Kastritis et al. · Leukemia · 2017 · 348 citations · Full text

Hematological Malignancy, Proteasome Inhibitors, Relapsed Myeloma +10

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

María‐Victoria Mateos, Shaji Kumar, Meletios Α. Dimopoulos et al. · Blood Cancer Journal · 2020 · 260 citations · Full text

Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Andrew Spencer, Suzanne Lentzsch, Katja Weisel et al. · Haematologica · 2018 · 254 citations · Full text

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

María‐Victoria Mateos, Pieter Sonneveld, Vânia Hungria et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 145 citations · Full text

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti–IL-6) in multiple myeloma

Jesús F. San Miguel, Joan Bladé, Ofer Shpilberg et al. · Blood · 2014 · 138 citations · Full text